Abstract
BackgroundBAY81‐8973 (Kovaltry; Bayer, Berkeley, CA, USA) was reported with enhanced pharmacokinetic (PK) profiles compared with some other standard half‐life (SHL) factor VIII (FVIII) concentrates. Limited head‐to‐head comparative studies were conducted in a real‐world setting. ObjectiveTo make head‐to‐head comparisons of PK and clinical outcomes between Kovaltry and three other SHL FVIII concentrates. MethodsForty‐seven boys with severe hemophilia A were enrolled and divided into three groups according to their previously used FVIII concentrates (Kogenate FS, N = 22; Advate, N = 14; GreenMono, N = 11). Two separate PK tests were conducted in each participant with a five‐point assay during the study period from 6 months before switching to 6 months after switching. FVIII levels were detected by one‐stage assay, and PK profiles were calculated by noncompartmental assay. Annualized bleeding rates were collected through participant’ bleed logs. ResultsLonger half‐life time (Kogenate FS group: 14.4 vs 11.9 hours, P< .0001; Advate group: 13.4 vs 9.7 hours, P< .0001; GreenMono group: 15.1 vs 10.7 hours, P< .001]) and lower clearance (Kogenate FS group: 3.3 vs 3.9 mL/kg/h, P< .01; Advate group: 3.7 vs 5.9 mL/kg/h, P< .01; GreenMono group: 3.0 vs 5.1 mL/kg/h, P< .01) were observed with Kovaltry. In addition, longer mean residential time (P< .01) and higher area under the curve (P< .01) were demonstrated. No statistical difference was found in in vivo recovery between Kovaltry and the other FVIII products. Participants who switched to Kovaltry from three other FVIII concentrates with the same dosing regimens obtained higher trough FVIII levels and better protection with reduced annualized bleeding rates. ConclusionCompared with Kogenate FS, Advate, and GreenMono, Kovaltry showed enhanced PK profiles, which contributed to reduced bleeding rates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Research and Practice in Thrombosis and Haemostasis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.